Dare Bioscience Inc (DARE)

$2.09 -0.02 (-0.95%)
Market Cap 31.31M
Revenue (ttm) 1.03M
Net Income (ttm) -13.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,300.97%
Debt to Equity Ratio 0.00
Volume 124,000
Avg Vol 468,884
Day's Range N/A - N/A
Shares Out 14.98M
Stochastic %K 48%
Beta 1.03
Analysts Strong Sell
Price Target $10.25

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 926 7655
Address:
3655 Nobel Drive, Suite 260, San Diego, United States
Danzzzzzzzz
Danzzzzzzzz Jul. 2 at 10:03 AM
$DARE do your due dill
0 · Reply
Danzzzzzzzz
Danzzzzzzzz Jul. 2 at 10:02 AM
$DARE yep
1 · Reply
Danzzzzzzzz
Danzzzzzzzz Jul. 2 at 10:02 AM
$DARE 👍
0 · Reply
Danzzzzzzzz
Danzzzzzzzz Jul. 2 at 10:02 AM
$DARE target here?
0 · Reply
darebio
darebio Jul. 1 at 6:24 PM
$DARE Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform https://bit.ly/4wpdmbU
0 · Reply
focafoca99
focafoca99 Jul. 1 at 1:27 PM
$DARE debuts its first consumer product, the Flora Sync LF5 vaginal probiotic. https://www.rapidticker.com/news/dare-daré-bioscience-announces-flora-sync-a7062e
0 · Reply
StackingWins999
StackingWins999 Jul. 1 at 1:15 PM
$DARE so we’re transitioning from pre revenue bio to having revenue…
2 · Reply
TheGlennSantos
TheGlennSantos Jun. 29 at 2:25 PM
$DARE Looks like it’s waking up
0 · Reply
focafoca99
focafoca99 Jun. 25 at 1:25 PM
$DARE previewed its upcoming Flora Sync LF5 launch, a first consumer health product aimed at generating revenue. https://www.rapidticker.com/news/dare-daré-bioscience-highlights-revenue-opportunity-530b4d
0 · Reply
Flypaper1
Flypaper1 Jun. 19 at 4:07 PM
$DARE we may get some good news towards the end of next week from that conference. I don’t think I’ve ever seen a weekend. Ask price this high before, good things to come?👀
1 · Reply
Latest News on DARE
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

Jul 1, 2026, 8:55 AM EDT - 3 days ago

Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

Jun 25, 2026, 9:05 AM EDT - 9 days ago

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

Jun 18, 2026, 9:20 AM EDT - 16 days ago

Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026

Daré Bioscience Transcript: AGM 2026

Jun 11, 2026, 12:00 PM EDT - 23 days ago

Daré Bioscience Transcript: AGM 2026

Daré Bioscience Proxy statement: Proxy filing

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Proxy statement: Proxy filing

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Daré Bioscience Proxy statement: Proxy filing

Dare Bioscience receives NIH funding award notice to advance DARE-HPV

2026-05-26T12:19:36.000Z - 5 weeks ago

Dare Bioscience receives NIH funding award notice to advance DARE-HPV

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

May 26, 2026, 8:00 AM EDT - 5 weeks ago

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dare Bioscience initiates DARE-HPV clinical study

2026-05-18T12:14:40.000Z - 6 weeks ago

Dare Bioscience initiates DARE-HPV clinical study

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

May 18, 2026, 8:00 AM EDT - 6 weeks ago

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

Daré Bioscience Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 7 weeks ago

Daré Bioscience Earnings Call Transcript: Q1 2026

Daré Bioscience Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 7 weeks ago

Daré Bioscience Quarterly report: Q1 2026

Daré Bioscience Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 7 weeks ago

Daré Bioscience Earnings release: Q1 2026

Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:01 PM EDT - 7 weeks ago

Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update

Dare Bioscience reports positive interim Phase 3 results for Ovaprene

2026-05-12T19:41:03.000Z - 7 weeks ago

Dare Bioscience reports positive interim Phase 3 results for Ovaprene

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026

Daré Bioscience Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Daré Bioscience Proxy statement: Proxy filing

Daré Bioscience Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 3 months ago

Daré Bioscience Earnings Call Transcript: Q4 2025

Daré Bioscience Annual report: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 3 months ago

Daré Bioscience Annual report: Q4 2025

Daré Bioscience Earnings release: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 3 months ago

Daré Bioscience Earnings release: Q4 2025

Daré Bioscience Slides: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 3 months ago

Daré Bioscience Slides: Q4 2025

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

Mar 26, 2026, 4:01 PM EDT - 3 months ago

Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

On National Viagra Day, Women Finally Claim Their Turn:

Mar 23, 2026, 8:00 AM EDT - 3 months ago

On National Viagra Day, Women Finally Claim Their Turn:

Dare Bioscience receives NIH funding award notice for DARE-PTB1

2026-03-16T12:39:51.000Z - 3 months ago

Dare Bioscience receives NIH funding award notice for DARE-PTB1

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Mar 12, 2026, 8:00 AM EDT - 4 months ago

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Daré Bioscience Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:40 PM EST - 4 months ago

Daré Bioscience Transcript: TD Cowen 46th Annual Health Care Conference

Dare Bioscience announces FDA clearance of IND application for Dare-HPV

2026-02-23T13:22:55.000Z - 4 months ago

Dare Bioscience announces FDA clearance of IND application for Dare-HPV

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Feb 23, 2026, 8:00 AM EST - 4 months ago

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dare announces availability of telehealth consultations for DARE to PLAY

2026-02-11T13:23:08.000Z - 5 months ago

Dare announces availability of telehealth consultations for DARE to PLAY

Dare Bioscience announces providers in select states can prescribe DARE to PLAY

2025-12-10T13:10:49.000Z - 7 months ago

Dare Bioscience announces providers in select states can prescribe DARE to PLAY

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Dec 10, 2025, 8:00 AM EST - 7 months ago

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Dare Bioscience announces return of rights to Oveprene

2025-12-01T13:20:39.000Z - 7 months ago

Dare Bioscience announces return of rights to Oveprene

Dare Bioscience receives $3.6M in additional grant funding

2025-11-24T13:30:31.000Z - 7 months ago

Dare Bioscience receives $3.6M in additional grant funding

Daré Bioscience Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Daré Bioscience Earnings Call Transcript: Q3 2025

Daré Bioscience Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Daré Bioscience Quarterly report: Q3 2025

Daré Bioscience Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Daré Bioscience Earnings release: Q3 2025

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:01 PM EST - 8 months ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Dare Bioscience to host webinar on the DARE to PLAY

2025-11-11T13:10:31.000Z - 8 months ago

Dare Bioscience to host webinar on the DARE to PLAY

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Dare Bioscience to receive up to $300,000 to conduct landscape review

2025-11-03T13:20:56.000Z - 8 months ago

Dare Bioscience to receive up to $300,000 to conduct landscape review

Dare Bioscience receives $4M non-dilutive grant installment

2025-10-06T12:20:36.000Z - 9 months ago

Dare Bioscience receives $4M non-dilutive grant installment

Dare Bioscience to receive up to $499,000 to support preeclampsia research

2025-09-24T12:11:38.000Z - 10 months ago

Dare Bioscience to receive up to $499,000 to support preeclampsia research

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Sep 24, 2025, 8:00 AM EDT - 10 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Dare Bioscience upgraded to Buy from Hold at Maxim

2025-09-04T11:45:08.000Z - 10 months ago

Dare Bioscience upgraded to Buy from Hold at Maxim

Daré Bioscience Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Daré Bioscience Earnings Call Transcript: Q2 2025

Daré Bioscience Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Daré Bioscience Quarterly report: Q2 2025

Daré Bioscience Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Daré Bioscience Earnings release: Q2 2025

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 11 months ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Dare Bioscience, Rosy Wellness launch first phase to support DARE to PLAY

2025-07-29T12:21:48.000Z - 1 year ago

Dare Bioscience, Rosy Wellness launch first phase to support DARE to PLAY

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 21, 2025, 1:47 PM EDT - 1 year ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Dare Bioscience to host webinar on Sildenafil cream

2025-07-21T12:27:31.000Z - 1 year ago

Dare Bioscience to host webinar on Sildenafil cream

Why Is Daré Bioscience Stock (DARE) Up 240% Today?

2025-07-15T00:37:00.000Z - 1 year ago

Why Is Daré Bioscience Stock (DARE) Up 240% Today?

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:00 PM EDT - 1 year ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience Proxy statement: Proxy Filing

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Slides: Corporate Presentation

Jun 9, 2025, 7:00 AM EDT - 1 year ago

Daré Bioscience Slides: Corporate Presentation

Daré Bioscience Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q1 2025

Daré Bioscience Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Quarterly report: Q1 2025

Daré Bioscience Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings release: Q1 2025

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Transcript: Jones Healthcare and Technology Innovation Conference 2025

Apr 9, 2025, 4:00 PM EDT - 1 year ago

Daré Bioscience Transcript: Jones Healthcare and Technology Innovation Conference 2025

Daré Bioscience Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings Call Transcript: Q4 2024

Daré Bioscience Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Earnings release: Q4 2024

Daré Bioscience Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Daré Bioscience Annual report: Q4 2024

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Feb 6, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Daré Bioscience Registration statement: Registration Filing

Nov 15, 2024, 7:00 AM EST - 1 year ago

Daré Bioscience Registration statement: Registration Filing

Daré Bioscience Earnings Call Transcript: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Earnings Call Transcript: Q3 2024

Daré Bioscience Earnings release: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Earnings release: Q3 2024

Daré Bioscience Quarterly report: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Quarterly report: Q3 2024

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Daré Bioscience Earnings Call Transcript: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q2 2024

Daré Bioscience Quarterly report: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Quarterly report: Q2 2024

Daré Bioscience Earnings release: Q2 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings release: Q2 2024

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 12, 2024, 4:01 PM EDT - 2 years ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 19, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Jul 1, 2024, 6:54 AM EDT - 2 years ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Daré Bioscience Announces Reverse Stock Split

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Reverse Stock Split

Daré Bioscience Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q1 2024

Daré Bioscience Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Quarterly report: Q1 2024

Daré Bioscience Earnings release: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings release: Q1 2024

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 14, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

May 2, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Daré Bioscience Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Proxy statement: Proxy Filing

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience Registration statement: Registration Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Registration statement: Registration Filing

Daré Bioscience Registration statement: Registration Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Registration statement: Registration Filing

Daré Bioscience Earnings Call Transcript: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings Call Transcript: Q4 2023

Daré Bioscience Annual report: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Annual report: Q4 2023

Daré Bioscience Earnings release: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Daré Bioscience Earnings release: Q4 2023

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

This overlooked corner of women's health could be a $350 billion market opportunity

Mar 15, 2024, 2:33 PM EDT - 2 years ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 31, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 26, 2024, 4:30 PM EST - 2 years ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 17, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Jan 4, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 26, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 20, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Danzzzzzzzz
Danzzzzzzzz Jul. 2 at 10:03 AM
$DARE do your due dill
0 · Reply
Danzzzzzzzz
Danzzzzzzzz Jul. 2 at 10:02 AM
$DARE yep
1 · Reply
Danzzzzzzzz
Danzzzzzzzz Jul. 2 at 10:02 AM
$DARE 👍
0 · Reply
Danzzzzzzzz
Danzzzzzzzz Jul. 2 at 10:02 AM
$DARE target here?
0 · Reply
darebio
darebio Jul. 1 at 6:24 PM
$DARE Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform https://bit.ly/4wpdmbU
0 · Reply
focafoca99
focafoca99 Jul. 1 at 1:27 PM
$DARE debuts its first consumer product, the Flora Sync LF5 vaginal probiotic. https://www.rapidticker.com/news/dare-daré-bioscience-announces-flora-sync-a7062e
0 · Reply
StackingWins999
StackingWins999 Jul. 1 at 1:15 PM
$DARE so we’re transitioning from pre revenue bio to having revenue…
2 · Reply
TheGlennSantos
TheGlennSantos Jun. 29 at 2:25 PM
$DARE Looks like it’s waking up
0 · Reply
focafoca99
focafoca99 Jun. 25 at 1:25 PM
$DARE previewed its upcoming Flora Sync LF5 launch, a first consumer health product aimed at generating revenue. https://www.rapidticker.com/news/dare-daré-bioscience-highlights-revenue-opportunity-530b4d
0 · Reply
Flypaper1
Flypaper1 Jun. 19 at 4:07 PM
$DARE we may get some good news towards the end of next week from that conference. I don’t think I’ve ever seen a weekend. Ask price this high before, good things to come?👀
1 · Reply
darebio
darebio Jun. 18 at 4:28 PM
$DARE to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-showcase-leadership-womens-health-innovation-bio
2 · Reply
focafoca99
focafoca99 Jun. 18 at 1:30 PM
$DARE engages at BIO International Convention 2026 as CEO Sabrina Martucci Johnson presents on women’s health leadership. https://www.rapidticker.com/news/dare-daré-bioscience-to-showcase-leadership-9c94b6
0 · Reply
Jscott76
Jscott76 Jun. 16 at 8:00 PM
$DARE some fun volume towards the end!
0 · Reply
StackingWins999
StackingWins999 Jun. 12 at 9:35 PM
$DARE primed and ready to roll… 📈📈📈
2 · Reply
focafoca99
focafoca99 Jun. 12 at 8:10 PM
$DARE awarded a 1.5 million‑share increase to its 2022 Stock Incentive Plan following shareholder approval. https://www.rapidticker.com/news/dare-sec-filing-fac090
0 · Reply
Lil_Fat_Donut_Boy
Lil_Fat_Donut_Boy Jun. 11 at 3:58 PM
$DARE lost 27k on this SOB
2 · Reply
SuperGreenToday
SuperGreenToday Jun. 10 at 8:53 PM
$DARE
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 10 at 12:15 AM
Crazy Runner Today 3,000% on $PAVS , Talking about Bullish Analysis on $DARE $HUMA $CNTB $GME and More Stocks https://www.youtube.com/watch?v=VgnuQc7798Q
1 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Jun. 5 at 8:17 PM
$DARE 🔜 1.70
0 · Reply
SnowBison
SnowBison Jun. 4 at 9:50 PM
$DARE
0 · Reply
Szopsson
Szopsson Jun. 4 at 2:04 PM
$DARE This year should be crucial
1 · Reply
HMIC
HMIC May. 31 at 10:40 AM
$DARE Working capital is always a serious consideration when trading biotechs.
0 · Reply